A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- NON RANDOMIZED · PARALLEL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 41
- Population
- ALL · 65 Years
- Duration
- 2020-01-15 to 2021-12-21
- Intervention
- Power resistance training
- Comparator
- Control group
- Outcomes measured
- Change from Baseline Glycosylated Hemoglobin (Hemoglobin A1c) at 12 weeks — 0 and 12 weeks.; Change from Baseline Homeostasis Model Assessment - Beta cells (HOMA2-B) at 12 weeks — 0 and 12 weeks.; Change from Baseline Homeostasis Model Assessment - Insuline Resistance (HOMA2-IR) at 12 weeks — 0 and 12 weeks.; Change from Baseline Fried frailty score at 6 and 12 weeks — 0, 6 and 12 weeks.; Change from Baseline Functional capacity at 6 and 12 weeks — 0, 6 and 12 weeks.; Change from Baseline Disability at 6 and 12 weeks — 0, 6 and 12 weeks.; Functional mobility at 6 and 12 weeks — 0, 6 and 12 weeks.; Change from Baseline Muscular power at 6 and 12 weeks — 0, 6 and 12 weeks.; Change from Baseline Levels of strength at 6 and 12 weeks — 0, 6 and 12 weeks.; Change from Baseline Bone Mineral Density at 12 weeks — 0 and 12 weeks.; Change from Baseline Pigment Epitelium Derived Factor (PEDF) at 12 weeks — 0 and 12 weeks.; Genotyping of TCF7L2 (rs7903146) — 0 week.; Genotyping of TM6SF2 (rs10401969) — 0 week.; Genotyping of HLA (rs2854275) — 0 week.; Change from Baseline Body Mass Index at 6 and 12 weeks — 0, 6 and 12 weeks.; Change from Baseline Waist circumference at 6 and 12 weeks — 0, 6 and 12 weeks.; Change from Baseline Blood pressure (systolic and diastolic) at 6 and 12 weeks — 0, 6 and 12 weeks.; Change from Baseline Concentration of Triglycerides at 12 weeks — 0 and 12 weeks.; Change from Baseline Concentration of Total Cholesterol at 12 weeks — 0 and 12 weeks.; Change from Baseline Concentration of HDL Cholesterol at 12 weeks — 0 and 12 weeks.
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Resistance training · 100%Title contains controlled term: strength training. Source terminology contains: resistance training. Title supplies longevity context: older adult. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.